Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 6/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126019 | 1.00 | PARK7 (0.39) | PARK7RARBMCL1BCL2A1MEN1 | |
| SCHEMBL5118341 | 1.00 | PARK7 (0.39) | PARK7RARBMCL1BCL2A1MEN1 | |
| SCHEMBL5110144 | 0.96 | RARB (0.37) | PARK7RARBMEN1ALDH1A1RARA | |
| SCHEMBL14287358 | 0.96 | RARB (0.37) | PARK7RARBMEN1ALDH1A1RARA | |
| SCHEMBL5110149 | 0.96 | RARB (0.37) | PARK7RARBMEN1ALDH1A1RARA | |
| SCHEMBL5126140 | 0.95 | RARB (0.38) | PARK7RARBMEN1ALDH1A1RARA | |
| SCHEMBL14287353 | 0.95 | RARB (0.38) | PARK7RARBMEN1ALDH1A1RARA | |
| SCHEMBL5119205 | 0.95 | RARB (0.38) | PARK7RARBMEN1ALDH1A1RARA | |
| SCHEMBL5113483 | 0.94 | PARK7 (0.40) | PARK7MCL1BCL2A1MEN1KMT2A | |
| SCHEMBL5113863 | 0.94 | PARK7 (0.40) | PARK7MCL1BCL2A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | PARK7 2430/4885RARB 37/4885MCL1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.